The treatment against respiratory infection -gene therapy with SiRNA-

抗PcrV免疫球蛋白可减轻慢性铜绿假单胞菌呼吸道感染引起的过度炎症反应，如炎症细胞的募集和促炎细胞因子的产生。提示抗PcrV-Ig G治疗慢性铜绿假单胞菌呼吸道感染可能是有效的。(Imamura Y，Yanagihara K，et al.在没有抗炎作用的情况下，泰利霉素通过抑制生物膜的形成而减少了活细菌的数量。目前的数据还表明，大环内酯类化合物和酮内酯类化合物对慢性呼吸道感染的作用存在差异。(Yanagihara K等)化疗2007年；53：10-13)西维来司他延长了严重肺炎球菌肺炎模型的生存时间。改善存活率的一个可能解释是西维来司通过抑制肺中NE的活性来防止组织损伤。由于这种减少的损害，西维来司组从血液中回收的活细菌数量低于对照组。因此，使用西维来特治疗可以提高死亡率。因此，NE抑制剂在治疗重症肺炎患者中可能有用。(Yanagihara K等)实验肺研究，3月；33(2)：71-80)

The anti-PcrV IgG reduced excessive inflammatory reactions, such as the recruitment of inflammatory cells and the production of pro-inflammatory cytokines, caused by chronic P.aeruginosa respiratory infection. These data suggest that treatment with anti-PcrV IgG may be useful in chronic P.aeruginosa respiratory infection. (Imamura Y, Yanagihara K, et al. Eur.Respir.J. 2007 in press)Telithromycin reduced the number of viable bacteria by inhibiting biofilm formation in the absence of an anti-inflammatory effect. The present data also indicated a difference between the effects of macrolides and ketolides against chronic respiratory infections. (Yanagihara K, et al. Chemotherapy 2007;53:10-13)Sivelestat prolonged survival in a severe pneumococcal pneumonia model. A possible explanation for the improved survival is that sivelestat prevents tissue damage by inhibiting NE activity in the lung. As a result of this reduced damage, the number of viable bacteria recovered from blood is lower in the sivelestat group than in the control group. Thus, improved mortality rates were seen with sivelestat treatment. NE inhibitors may therefore be useful in treating with patients with severe pneumonia. (Yanagihara K, et al. Experimental Lung Research, Mar;33(2):71-80)